Investment Analysts’ Weekly Ratings Changes for Biohaven (BHVN)

A number of research firms have changed their ratings and price targets for Biohaven (NYSE: BHVN):

• 3/7/2025 – Biohaven had its price target lowered by analysts at Morgan Stanley from $69.00 to $63.00. They now have an “overweight” rating on the stock.
• 3/5/2025 – Biohaven had its price target lowered by analysts at JPMorgan Chase & Co. from $72.00 to $68.00. They now have an “overweight” rating on the stock.
• 3/4/2025 – Biohaven had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock.
• 3/4/2025 – Biohaven had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
• 2/11/2025 – Biohaven is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $65.00 price target on the stock.

Biohaven Price Performance

NYSE:BHVN traded up $0.39 during trading hours on Monday, hitting $29.54. The stock had a trading volume of 248,598 shares, compared to its average volume of 1,070,778. The company has a 50 day simple moving average of $36.87 and a two-hundred day simple moving average of $42.01. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of -3.16 and a beta of 1.27. Biohaven Ltd. has a one year low of $26.80 and a one year high of $60.46.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Equities research analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insider Transactions at Biohaven

In related news, Director John W. Childs bought 29,000 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was bought at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the transaction, the director now owns 2,368,741 shares of the company’s stock, valued at approximately $85,132,551.54. The trade was a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 16.00% of the company’s stock.

Hedge Funds Weigh In On Biohaven

A number of hedge funds and other institutional investors have recently modified their holdings of BHVN. Citigroup Inc. boosted its position in Biohaven by 125.8% during the third quarter. Citigroup Inc. now owns 119,905 shares of the company’s stock valued at $5,992,000 after buying an additional 66,801 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Biohaven during the 3rd quarter worth approximately $1,339,000. JPMorgan Chase & Co. grew its position in Biohaven by 85.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after acquiring an additional 372,737 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Biohaven by 9.1% in the 4th quarter. Bank of New York Mellon Corp now owns 295,078 shares of the company’s stock worth $11,021,000 after purchasing an additional 24,703 shares during the period. Finally, XTX Topco Ltd lifted its position in Biohaven by 278.5% in the third quarter. XTX Topco Ltd now owns 32,510 shares of the company’s stock valued at $1,625,000 after purchasing an additional 23,921 shares during the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.